Actively Recruiting
Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of AZD4063 in Adults with Phospholamban R14del Dilated Cardiomyopathy
Led by AstraZeneca · Updated on 2026-09-04
23
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are assessing the safety, tolerability, and how the body processes pharmacokinetics AZD4063 in adults with phospholamban PLN R14del dilated cardiomyopathy. This phase 1, first-in-human, unblinded, sequential study focuses on participants with this specific genetic mutation and heart condition. The goal is to understand the effects of single ascending doses of AZD4063 given by subcutaneous injection. The study includes a screening period, a treatment period where participants receive a single dose of AZD4063 under the skin, and a follow-up period to monitor effects. There will be four initial dose groups and optional additional dose groups depending on emerging safety and pharmacokinetic data. The treatment is given once per participant in these dose escalation cohorts. Participants will undergo screening to confirm eligibility, receive one dose of the study drug, and be monitored during follow-up visits for up to 210 days depending on their cohort. Assessments include tracking adverse events, measuring drug levels in the blood and urine, and evaluating heart tissue samples for molecular changes. Safety monitoring will continue through the follow-up period to evaluate tolerability and drug behavior in the body.
CONDITIONS
Brief Title
A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here